Histone deacetylase inhibitors

Details Histone deacetylase inhibitors Histone deacetylase inhibitors

2007-12-25

2007-12-25

Wang, Shengjun (Department: 1617)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Radical -xh acid, or anhydride, acid halide or salt thereof...

Reexamination Certificate

active

09812945

ABSTRACT:
Histone deacetylase is a metallo-enzyme with zinc at the active site. Compounds having a zinc-binding moiety, such as, for example, a hydroxamic acid group or a carboxylic acid group, can inhibit histone deacetylase. Histone deacetylase inhibition can repress gene expression, including expression of genes related to tumor suppression. Accordingly, inhibition of histone deacetylase can provide an alternate route for treating cancer, hematological disorders, e.g., hemoglobinopathies, and genetic related metabolic disorders, e.g., cystic fibrosis and adrenoleukodystrophy.

REFERENCES:
patent: 2680755 (1954-06-01), Robeson et al.
patent: 2840586 (1958-06-01), Inhoffen
patent: 3479396 (1969-11-01), Buu-Hoi et al.
patent: 3551574 (1970-12-01), Frohberger et al.
patent: 3624127 (1971-11-01), Shaw et al.
patent: 3674884 (1972-07-01), Moritani et al.
patent: 3687955 (1972-08-01), Cerbati et al.
patent: 3755604 (1973-08-01), Gallo
patent: 3781314 (1973-12-01), Bollag et al.
patent: 3886278 (1975-05-01), Gallo
patent: 3909353 (1975-09-01), Tsuchida et al.
patent: 3978100 (1976-08-01), Fujita et al.
patent: 3984440 (1976-10-01), Bollag et al.
patent: 4011339 (1977-03-01), Galantay et al.
patent: 4024182 (1977-05-01), Kathawala
patent: 4044149 (1977-08-01), Fields et al.
patent: 4048332 (1977-09-01), Adams et al.
patent: 4061656 (1977-12-01), Klaus et al.
patent: 4081476 (1978-03-01), Anderson et al.
patent: 4113858 (1978-09-01), Hashim
patent: 4116975 (1978-09-01), Klaus et al.
patent: 4127722 (1978-11-01), Lafon
patent: 4127723 (1978-11-01), Yankee
patent: 4130653 (1978-12-01), Giroux et al.
patent: 4171318 (1979-10-01), Chan et al.
patent: 4188338 (1980-02-01), Bruins et al.
patent: 4193931 (1980-03-01), Loeliger
patent: 4211783 (1980-07-01), Shepherd
patent: 4258057 (1981-03-01), Bartmann et al.
patent: 4288253 (1981-09-01), Venable
patent: 4309357 (1982-01-01), Chiusoli et al.
patent: 4309407 (1982-01-01), Lautenschläger et al.
patent: 4335054 (1982-06-01), Blaser et al.
patent: 4355168 (1982-10-01), Chiusoli et al.
patent: 4371614 (1983-02-01), Anderson et al.
patent: 4388459 (1983-06-01), Shepherd
patent: 4439443 (1984-03-01), Giroux
patent: 4440940 (1984-04-01), Shepherd
patent: 4472430 (1984-09-01), Loev et al.
patent: 4504494 (1985-03-01), Grollier et al.
patent: 4505930 (1985-03-01), Loev et al.
patent: 4534979 (1985-08-01), Loev et al.
patent: 4545984 (1985-10-01), Möller et al.
patent: 4564476 (1986-01-01), Ho
patent: 4604407 (1986-08-01), Haslanger et al.
patent: 4605669 (1986-08-01), Summers, Jr.
patent: 4607053 (1986-08-01), Karanewsky et al.
patent: 4608390 (1986-08-01), Summers, Jr.
patent: 4619945 (1986-10-01), Loev et al.
patent: 4621099 (1986-11-01), Loev et al.
patent: 4623661 (1986-11-01), Summers, Jr.
patent: 4638011 (1987-01-01), Das
patent: 4699920 (1987-10-01), Skuballa et al.
patent: 4709076 (1987-11-01), Bombardelli et al.
patent: 4722939 (1988-02-01), Loev et al.
patent: 4731382 (1988-03-01), Zusi et al.
patent: 4753934 (1988-06-01), Nickl et al.
patent: 4791133 (1988-12-01), Djuric et al.
patent: 4820828 (1989-04-01), Demers et al.
patent: 4833257 (1989-05-01), Pettit et al.
patent: 4950467 (1990-08-01), Phalangas et al.
patent: 4981865 (1991-01-01), Belliotti et al.
patent: 4985436 (1991-01-01), Pettit
patent: 5028629 (1991-07-01), Hite et al.
patent: 5064860 (1991-11-01), Mueller et al.
patent: 5075330 (1991-12-01), Belliotti et al.
patent: 5084214 (1992-01-01), Kita et al.
patent: 5089524 (1992-02-01), Collins et al.
patent: 5091569 (1992-02-01), Matsumoto et al.
patent: 5112846 (1992-05-01), Belliotti et al.
patent: 5141959 (1992-08-01), Carroll et al.
patent: 5235068 (1993-08-01), Minai et al.
patent: 5244922 (1993-09-01), Burzynski
patent: 5246955 (1993-09-01), Skibo et al.
patent: 5264424 (1993-11-01), Della Valle et al.
patent: 5272180 (1993-12-01), Hashimoto et al.
patent: 5320833 (1994-06-01), Deckers et al.
patent: 5369108 (1994-11-01), Breslow et al.
patent: 5385942 (1995-01-01), Abe et al.
patent: 5420160 (1995-05-01), Gayer et al.
patent: 5466718 (1995-11-01), Nakatsu et al.
patent: 5475022 (1995-12-01), Chandraratna
patent: 5486540 (1996-01-01), Andrews
patent: 5525629 (1996-06-01), Crimmin et al.
patent: 5541155 (1996-07-01), Leone-Bay et al.
patent: 5547988 (1996-08-01), Yu et al.
patent: 5602135 (1997-02-01), Chandraratna
patent: 5607978 (1997-03-01), Woodward et al.
patent: 5643949 (1997-07-01), Van Scott et al.
patent: 5672746 (1997-09-01), Nau et al.
patent: 5677320 (1997-10-01), Chandraratna
patent: 5688819 (1997-11-01), Woodward et al.
patent: 5696162 (1997-12-01), Chandraratna
patent: 5705167 (1998-01-01), Bernardon et al.
patent: 5710178 (1998-01-01), Samid
patent: 5872152 (1999-02-01), Brown et al.
patent: 6057369 (2000-05-01), Groneberg et al.
patent: 6451334 (2002-09-01), Perrine
patent: RE37947 (2002-12-01), Bernardon et al.
patent: 6511990 (2003-01-01), Breslow et al.
patent: 0 161 939 (1985-11-01), None
patent: 0 199 151 (1986-10-01), None
patent: WO98/55449 (1998-12-01), None
patent: WO 01/18171 (2001-03-01), None
patent: WO 01/38322 (2001-05-01), None
Richon et al., A class of hybrid polar inducers of transformed cell differentiation inhibits histone descetylase, abstract, Mar. 1998.
Marks et al., “Histone Daecetylase Inhibitors”, J. of Natl. Cancer Inst., vol. 92 No. 15 1210-1216 (2000).
Richon et al. ‘A class of hybrid polar inducers of transformed cell diferentiation inhibits histone deacetylases,’ Proc. Natl. Acad. Sci. USA 1998, vol. 95, pp. 3003-3007.
Andrews et al., “Anti-malarial effect of histone deacetylation inhibitors and mammalian tumour cytodifferentiating agents”, International Journal for Parasitology, 30, pp. 761-768, (2000).
Collins et al., “Oral Sodium Phenylbutyrate Therapy in Homozygous β Thalassemia: A Clinical Trial”, Blood, vol. 85, No. 1, pp. 43-49, (1995).
Finnin et al., “Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors”, Nature, vol. 401, pp. 188-193, (1999).
Fruehauf et al., “In Vitro Determination of Drug Response: A Discussion of Clinical Applications”, Principles & Practice of Oncology, vol. 7 No. 12, pp. 1-16, (1993).
Gore et al., “Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors”, Exp. Opin. Invest. Drugs, 9(12), pp. 2923-2934, (2000).
Hoffman et al., “A non-isotopic assay for histone deacetylase activity”, Nucleic Acids Research, vol. 27, No. 9, pp. 2057-2058, (1999).
Kemp et al., “Gene redundancy and pharmacological gene therapy: Implications for X-linked adrenoleukodystrophy”, Nature Medicine, vol. 4, No. 11, pp. 1261-1268, (1998).
Kim et al., “Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase”, Oncogene, vol. 18, pp. 2461-2470, (1999).
Marks et al., “Histone Deacetylase Inhibitors: Inducers of Differentiation or Apoptosis of Transformed Cells”, Journal of the National Cancer Institute, vol. 92, No. 15, pp. 1210-1216, (2000).
Remiszewski et al., “Synthesis and in Vitro SAR of Straight Chain Hydroxamate Histone Deacetylase Inhibitors”, Proceedings of the AACR, vol. 42, No. 4976, (Feb. 27, 2001).
Rubenstein et al., “In Vitro Pharmacologic Restoration of CFTR-mediated Chloride Transport with Sodium 4-Phenylbutyrate in Cystic Fibrosis Epithelial Cells Containing ΔF508-CFTR”, J. Clin. Invest., vol. 100, No. 10, pp. 2457-2465, (1997).
Sandler et al., “Organic Functional Group Preparations”, Academic Press, New York and London, vol. III, pp. 436-437, (1972).
Saunders et al., Histone deacetylase inhibitors: novel anticancer agents, Exp. Opin. Invest. Drugs, 8(10), pp. 1611-1621, (1999).
Taunton et al., “A Mammalian Histone Deacetylase Related to the Yeast Transcriptional Regulator Rpd3p”, Science, vol. 272, pp. 408-411, (1996).
Summers et al. “Hydroxamic Acid Inhibitors of 5-Lipoxygenase: Quantitative Structure-Activity

Affiliated with

Also associated with

Rating

Histone deacetylase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Histone deacetylase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Histone deacetylase inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3842344